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Background-—Although current guidelines now deﬁne heart failure with midrange ejection fraction (HFmrEF) as HF with a left
ventricular EF of 40% to 49%, there are limited data on response to guideline-directed medical therapy in patients with HFmrEF. The
current study aimed to evaluate the association between b-blocker, renin-angiotensin system blocker (RASB), or aldosterone
antagonist (AA) treatment with clinical outcome in patients with HFmrEF.
Methods and Results-—We performed a patient-level pooled analysis on 1144 patients with HFmrEF who were hospitalized for
acute HF from the KorHF (Korean Heart Failure) and KorAHF (Korean Acute Heart Failure) registries. The study population was
divided between use of b-blocker, RASB, or AA to evaluate the guideline-directed medical therapy in patients with HFmrEF.
Sensitivity analyses, including propensity score matching and inverse-probability-weighted methods, were performed. The use of
b-blocker in the discharge group showed signiﬁcantly lower rates of all-cause mortality compared with those who did not use a
b-blocker (b-blocker versus no b-blocker, 30.7% versus 38.2%; hazard ratio, 0.758; 95% conﬁdence interval, 0.615–0.934;
P=0.009). Similarly, the RASB use in the discharge group was associated with the lower risk of mortality compared with no use of
RASB (RASB versus no RASB, 31.9% versus 38.1%; hazard ratio, 0.76; 95% conﬁdence interval, 0.618–0.946; P=0.013). However,
there was no signiﬁcant difference in all-cause mortality between AA and no AA in the discharge group (AA versus no AA, 34.2%
versus 34.0%; hazard ratio, 1.063; 95% conﬁdence interval, 0.858–1.317; P=0.578). Multiple sensitivity analyses showed similar
trends.
Conclusions-—For treatment of acute HFmrEF after hospitalization, b-blocker and RASB therapies on discharge were associated
with reduced risk of all-cause mortality.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01389843. ( J Am Heart Assoc. 2018;7:
e009806. DOI: 10.1161/JAHA.118.009806.)
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I t is well known that neurohormonal antagonists (b-blocker,renin-angiotensin system blocker [RASB], and aldosterone
antagonist [AA]) reduce morbidity and mortality in patients
with heart failure with reduced ejection fraction (HFrEF).1–8
b-Blocker and RASB are recommended as class IA indications
(unless contraindicated or not tolerated) in all symptomatic
patients by the current guidelines.9,10 An AA is also recom-
mended for patients with HFrEF who remain symptomatic
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despite treatment with RASB and b-blocker. However, guide-
line-directed medical therapy (GDMT) has not been proved to
reduce mortality and morbidity in patients with HF with
preserved EF (HFpEF).
The new European Society of Cardiology guidelines suggest
that patients with HF should be categorized as HFpEF (EF
≥50%), HFrEF (EF <40%), and HF with midrange EF (HFmrEF; EF
40%–49%).9 However, it is unclear if the prognosis of HFmrEF is
similar to that of HFpEF, HFrEF, or a new “gray area” group.11–19
Furthermore, there are limited data about the effect of GDMT to
reduce morbidity and mortality for patients with HFmrEF.
Therefore, using 2 nationwide prospective multicenter reg-
istries from Republic of Korea, we investigated the association
between GDMT, including b-blocker, RASB, and AA, on
discharge and clinical outcome in patients with HFmrEF.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Pooled Patient Population
The current study population was extracted from patient-
pooled cohorts from 2 nationwide, prospective, multicenter
registries. First, the KorHF (Korean Heart Failure) registry
included 3200 patients hospitalized for acute HF (AHF) from
24 hospitals in Korea, between June 2004 and April 2009.20
All consecutive patients with HF were enrolled, and HF was
diagnosed on admission according to the Framingham
criteria.21 Second, the KorAHF (Korean Acute Heart Failure)
registry recruited 5625 hospitalized patients with AHF from 10
tertiary hospitals in Korea, between March 2011 and February
2014.22 Inclusion criteria of this registry were signs or
symptoms of HF and at least 1 objective sign of lung
congestion, left ventricular systolic dysfunction, or structural
heart disease. There were no exclusion criteria in either
registry, except withdrawal of consent. Patients with HF were
categorized as having HFpEF (EF ≥50%), HFrEF (EF <40%), or
HFmrEF (EF 40%–49%), according to the recent guidelines.9 Left
ventricular EF (LVEF) was assessed by the biplane Simpson
technique, M-mode, or visual estimation.23 From the total
pooled population of 8825 patients, 1144 with HFmrEF were
selected for the current analysis (Figure 1). To identify the
association between GDMT and clinical outcomes for patients
with HFmrEF, the study population was stratiﬁed by use of each
evidence-basedmedical therapy at discharge (b-blocker, RASB,
or AA). RASB included angiotensin-converting enzyme inhibitor
or angiotensin receptor blocker. The primary outcome was all-
cause mortality during follow-up. The study protocol was
approved by the Institutional Review Board at each participating
center, and all patients provided written informed consent
before enrollment. This study protocol was conducted accord-
ing to the principles of the Declaration of Helsinki.
Data Collection and Follow-Up Information
In both registries, patient demographics, baseline character-
istics, medical history, clinical presentation, laboratory test
results, treatments, and outcomes from the initial presentation
through discharge were recorded via a web-based case-report
form by each attending physician. After discharge, follow-up
data, including all-cause mortality, death from HF aggravation,
and rehospitalization for HF aggravation, were prospectively
collected using medical records or telephone interviews.
Mortality data for patients who were unavailable for follow-up
were obtained from the National Insurance Data or National
Death Records. All clinical events were monitored and veriﬁed
by a Clinical Event Committee composed of independent
experts in HF who did not participate in patient enrollment for
this study. The mean observational periods of the KorHF and
KorAHF registries were 1.7 years (range, 0.1–4.9 years) and
2.1 years (range, 0.1–4.2 years), respectively. Follow-up of
patients in the KorAHF registry is planned until 2018.
Statistical Analysis
Continuous variables were compared using the Welch’s t test,
which is broadly applicable without the need for an equal
Clinical Perspective
What Is New?
• Among patients with heart failure with midrange ejection
fraction (HFmrEF) who were admitted for acute HF, patients
treated with b-blocker or renin-angiotensin system blocker
at discharge had lower risk of all-cause mortality compared
with those who did not use b-blocker or renin-angiotensin
system blocker.
What Are the Clinical Implications?
• The current guidelines suggest that HFmrEF might be
managed in the same way as HF with preserved EF because
there is limited evidence of the effect of guideline-directed
medical therapy in patients with HFmrEF.
• Our results suggest that the use of b-blocker and renin-
angiotensin system blocker in HFmrEF is associated with
reduced risk of mortality, similar to heart failure with
reduced ejection fraction.
• Future randomized controlled trials are warranted to clarify
whether guideline-directed medical therapy would improve
prognosis of patients with HFmrEF.
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variance assumption. The v2 test was performed to compare
the categorical variables. Cumulative incidences of all-cause
mortality were assessed by Kaplan-Meier estimates, and
signiﬁcance levels were compared using the log-rank test. To
compare risk of all-cause mortality between use and no use of
b-blocker, RASB, or AA at discharge, we used Cox propor-
tional hazards models stratiﬁed by each GDMT. Multiple
sensitivity analyses, including inverse-probability-weighted
(IPW) and propensity score matching methods, were per-
formed to reduce selection bias and to adjust the baseline
difference. Enrolled subjects were matched 1:1 for b-blocker
versus no b-blocker, RASB versus no RASB, and AA versus no
AA comparisons using a caliper of width 0.2. Variables
selected for use in the propensity score matching and IPW
analysis included age, sex, body mass index, current smoker,
hypertension, diabetes mellitus, chronic kidney disease,
previous myocardial infarction, previous cerebrovascular
accident, previous HF admission, de novo AHF, New York
Heart Association classiﬁcation, ischemic cardiomyopathy,
dilated cardiomyopathy, valvular heart disease, atrial ﬁbrilla-
tion, systolic blood pressure, LVEF, white blood cell count,
creatinine level, hemoglobin level, use of intravenous diuret-
ics, intravenous inotropes, mechanical ventilation, transfu-
sion, intensive care unit admission, and use of other GDMT
(Table S1). Balance of baseline difference after propensity
score matching or IPW adjustment was assessed by calcu-
lating percentage standardized mean differences. Percentage
standardized mean differences after propensity score match-
ing or IPW adjustment were within 10% across all matched
covariates, demonstrating successful balance between com-
parative groups (Table S1). Stratiﬁed and IPW adjusted Cox
proportional hazard models were used to compare outcomes
of matched groups. All statistical analyses were performed
using R Statistical Software, version 3.4.3 (R Foundation for
Statistical Computing, Vienna, Austria), with P<0.05 consid-
ered statistically signiﬁcant.
Results
Baseline Characteristics
Among the total population of the pooled cohort, 59.1% of
patients presented with HFrEF, 26.0% of patients presented
with HFpEF, and 14.9% of patients presented with HFmrEF.
Among the 1144 patients with HFmrEF, b-blockers were
prescribed for 620 (54.2%), RASBs were prescribed for 737
(64.4%), and AAs were prescribed for 433 (37.8%) at
discharge (Table 1). The mean age of the study population
Figure 1. Study ﬂow. KorAHF indicates Korean Acute Heart Failure; KorHF, Korean Heart Failure; LVEF,
left ventricular ejection fraction.
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was 70.7 years, and 532 patients (46.5%) were men. The
most common cause for HFmrEF was ischemic cardiomyopa-
thy (47.6%). Table 2 presents baseline clinical characteristics
of patients with HFmrEF, according to use or not of each
GDMT at discharge.
Compared with the no b-blocker group, patients in the
b-blocker group had signiﬁcantly higher prevalence of hyper-
tension and diabetes mellitus. Ischemic cause was more
frequent in the b-blocker group, but valvular heart disease and
atrial ﬁbrillation were more frequent in the no b-blocker group.
Patients with RASB at discharge also had signiﬁcantly higher
hypertension. Systolic and diastolic pressure at admission and
history of HF admission were signiﬁcantly higher in the RASB
group than in the no RASB group. Both the b-blocker and RASB
groups were less likely to receive treatment with intravenous
inotropes during admission compared with the no b-blocker
and no RASB groups. Compared with the no AA group, the AA
group had a higher proportion of female patients and patients
with a history of HF admission, New York Heart Association
classiﬁcation ≥3, and use of intravenous diuretics, but a lower
proportion of patients with diabetes mellitus, chronic kidney
disease, and ischemic cause. Also, the AA group had lower
levels of creatinine than the no AA group. There was no
signiﬁcant difference in LVEF in all stratiﬁed groups.
Propensity score matching was performed with 375
matched pairs of patients for comparison between the
Table 1. Baseline Clinical Characteristics of the Total Study
Population
Characteristics
Value for All Patients
With Heart Failure With
Midrange Ejection
Fraction (N=1144)
Demographics
Age, y 70.713.4
Male sex 532 (46.5)
Body mass index, kg/m2 23.23.7
Cardiovascular risk factors
Current smoker 167 (14.7)
Hypertension 692 (60.5)
Diabetes mellitus 402 (35.1)
Chronic kidney disease 167 (14.6)
Previous myocardial infarction 190 (16.6)
Previous cerebrovascular accident 163 (14.3)
Previous heart failure admission 248 (21.7)
Presentation and cause of heart failure
De novo acute heart failure 457 (39.9)
NYHA class ≥3 901 (78.8)
Ischemic cardiomyopathy 544 (47.6)
Dilated cardiomyopathy 54 (4.7)
Valvular heart disease 162 (14.2)
Arrhythmia 333 (29.1)
Atrial fibrillation 295 (25.8)
Hemodynamic parameters at admission
Systolic blood pressure, mm Hg 137.032.0
Diastolic blood pressure, mm Hg 79.919.1
Pulse rate, beats/min 92.027.0
Left ventricular ejection fraction, % 44.22.8
Laboratory data
WBCs, /mm3 8908.24282.1
Creatinine, mg/dL 1.61.7
Hemoglobin, g/dL 11.92.3
NT-proBNP, pg/mL 9149.210 378.0
In-hospital management
Intravenous diuretics 827 (72.3)
Intravenous inotropes 265 (23.2)
Digoxin 276 (24.1)
Nitrates 595 (52.0)
Mechanical ventilation 125 (10.9)
Transfusion 198 (17.3)
ICU admission 543 (47.5)
Length of stay, d 9.0 (6.0–14.0)
Continued
Table 1. Continued
Characteristics
Value for All Patients
With Heart Failure With
Midrange Ejection
Fraction (N=1144)
Medications at discharge
b-Blocker 620 (54.2)
Renin-angiotensin system blocker* 737 (64.4)
Aldosterone antagonist 433 (37.8)
No use of the 3 drugs 170 (14.9)
b-Blocker only 97 (8.5)
Renin-angiotensin system blocker only 167 (14.6)
Aldosterone antagonist only 77 (6.7)
b-Blocker+renin-angiotensin system blocker 277 (24.2)
b-Blocker+aldosterone antagonist 63 (5.5)
Renin-angiotensin system
blocker+aldosterone antagonist
110 (9.6)
All the 3 drugs 183 (16.0)
Loop diuretics 898 (78.5)
Values are meanSD, median (quartile 1–quartile 3), or number (percentage). ICU
indicates intensive care unit; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
NYHA, New York Heart Association; WBC, white blood cell.
*Renin-angiotensin system blocker included angiotensin-converting enzyme inhibitor and
angiotensin receptor blocker.
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b-blocker and no b-blocker groups, 302 matched pairs of
patients for comparison between the RASB and no RASB
groups, and 362 matched pairs of patients for comparison
between the AA and no AA groups. The C statistics for the
propensity score model were 0.69 for b-blocker, 0.74 for
RASB, and 0.70 for AA (Hosmer-Lemeshow goodness of ﬁt,
P=0.94, P=0.81, and P=0.09, respectively).
Clinical Outcome
GDMT for HFpEF and HFrEF
Among patients with HFpEF, b-blocker, RASB, and AA at
discharge were not associated with reduced risk of all-cause
mortality compared with the no drug group (Figure S1).
b-Blocker and RASB at discharge were signiﬁcantly associated
with lower risk of all-cause mortality compared with no b-
blocker and no RASB at discharge in patients with HFrEF
(Figure S2). However, among patients with HFrEF, there was no
signiﬁcant difference in the rates of all-causemortality between
the AA at discharge and no AA at discharge groups (Figure S2).
Overall population of HFmrEF
The median follow-up duration was 27 months (interquartile
range, 17–37 months). A total of 354 patients (30.9%) died
during a 3-year follow-up period. Patients prescribed
b-blocker at discharge showed a signiﬁcantly lower risk of
all-cause mortality compared with those without b-blocker at
discharge (b-blocker versus no b-blocker, 30.7% versus
38.2%; hazard ratio [HR], 0.758; 95% conﬁdence interval
[CI], 0.615–0.934; P=0.009) (Table 3). Similarly, prescription
of RASB at discharge was associated with lower rates of all-
cause mortality compared with those without RASB at
discharge (RASB versus no RASB, 31.9% versus 38.1%; HR,
0.76; 95% CI, 0.618–0.946; P=0.013) (Table 3). However,
there was no signiﬁcant difference in the rate of all-cause
mortality between the AA and no AA at discharge groups (AA
versus no AA, 34.2% versus 34.0%; HR, 1.063; 95% CI, 0.858–
1.317; P=0.578) (Table 3).
Sensitivity analyses
After 1:1 propensity score matching of 375 pairs for use of
b-blocker or not, the b-blocker at discharge group showed
signiﬁcantly lower risk of mortality than the no b-blocker group
among patients with HFmrEF (29.5% versus 37.8%; HR, 0.734;
95% CI, 0.565–0.954; P=0.021) (Table 3, Figure 2A). RASB at
dischargewas associatedwith signiﬁcantly lower risk of all-cause
mortality comparedwith noRASB at discharge in the 302 pairs of
propensity-matched cohorts (32.5% versus 39.6%; HR, 0.755;
95% CI, 0.570–0.999; P=0.048) (Table 3, Figure 2B). However,
all-cause mortality rates did not differ between the AA and no AA
groups in the 362 pairs of propensity-matched populations
(35.1% versus 33.3%; HR, 1.176; 95% CI, 0.904–1.526; P=0.229)
(Table 3, Figure 2C). IPW analysis consistently showed similar
outcomes between the stratiﬁed groups (Table 3).
Use of b-blocker and RASB in patients with HFmrEF
To evaluate the combination effect ofb-blocker and RASB, which
were initially recommended for patients with HF by the current
guidelines, we stratiﬁed 4 groups (no drug, b-blocker only, RASB
only, and b-blocker plus RASB) and compared the clinical
outcomes. On a multivariable Cox proportional hazard model of
total population, the b-blocker only, RASB only, and b-blocker
plus RASB groups associated with lower risk of all-cause
mortality compared with the no drug group (Table 4, Figure 3).
The lowest HR and cumulative incidence of all-cause mortality
were observed in the b-blocker plus RASB group onmultivariable
analysis. Variables selected for a multivariate model included
age, sex, body mass index, hypertension, diabetes mellitus,
Table 3. Comparison of All-Cause Mortality During Follow-Up, According to GDMT at Discharge
Variable Cumulative Incidence, No. %*
Univariate Analysis IPW Adjusted Analysis PS-Matched Analysis
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
b-Blocker at discharge (375 pairs)
No (n=524) 183 (38.2) 1.000 Reference NA 1.000 Reference NA 1.000 Reference NA
Yes (n=620) 171 (30.7) 0.758 0.615–0.934 0.009 0.827 0.708–0.967 0.017 0.734 0.565–0.954 0.021
Renin-angiotensin system blocker at discharge (302 pairs)
No (n=407) 143 (38.1) 1.000 Reference NA 1.000 Reference NA 1.000 Reference NA
Yes (n=737) 211 (31.9) 0.765 0.618–0.946 0.013 0.814 0.698–0.950 0.009 0.755 0.570–0.999 0.048
Aldosterone antagonist at discharge (362 pairs)
No (n=711) 218 (34.0) 1.000 Reference NA 1.000 Reference NA 1.000 Reference NA
Yes (n=433) 136 (34.2) 1.063 0.858–1.317 0.578 1.138 0.974–1.330 0.103 1.176 0.904–1.526 0.229
CI indicates conﬁdence interval; GDMT, guideline-directed medical therapy; HR, hazard ratio; IPW, inverse probability weighted; NA, not applicable; PS, propensity score.
*Cumulative incidences of all-cause mortality are presented as Kaplan-Meier estimates.
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chronic kidney disease, current smoker, New York Heart
Association class ≥3, history of cerebrovascular events, history
of HF admission, history of myocardial infarction, ischemic
cause, dilated cardiomyopathy, atrial ﬁbrillation, valvular heart
disease, systolic blood pressure, hemoglobin, white blood cell
count, LVEF, and use of intravenous inotropes during admission.
Other predictors of all-cause mortality among patients with
HFmrEF are presented in Table 4.
Use of digoxin and nitrates in patients with HFmrEF
We performed the additional analysis for evaluating the
effects of digoxin and nitrates on the risk of mortality in
Figure 2. Comparison of all-cause mortality at 3 years, according to use of guideline-directed medical therapy among each propensity-
matched population. Kaplan-Meier curves for all-cause mortality of patients with acute heart failure with midrange ejection fraction, according to
use of b-blocker (blue line) or no b-blocker (red line) in the 375 pairs from a propensity score–matched population (A), use of renin-angiotensin
system blocker (RASB; blue line) or no RASB (red line) in the 302 pairs from a propensity-matched population (B), and use of aldosterone
antagonist (AA; blue line) or no AA (red line) in the 362 pairs from a propensity-matched population (C), are presented.
Table 4. Predictors of All-Cause Mortality in Patients With
HFmrEF
Variable Adjusted HR (95% CI)* P Value
Use of b-blocker and/or RASB (n=1144)
No drug (n=247) 1.000 (Reference) NA
b-Blocker only (n=160) 0.667 (0.464–0.960) 0.029
RASB only (n=277) 0.673 (0.496–0.915) 0.011
b-Blocker and RASB (n=460) 0.636 (0.476–0.851) 0.002
Age (per 1 increase) 1.042 (1.031–1.054) <0.001
Body mass index (per 1 increase) 0.964 (0.932–0.997) 0.031
Hemoglobin (per 1 increase) 0.858 (0.814–0.904) <0.001
WBCs (per 1000 increase) 1.045 (1.022–1.070) <0.001
Male sex 1.453 (1.156–1.828) 0.001
Chronic kidney disease 1.430 (1.071–1.909) 0.015
Previous heart failure admission 1.384 (1.057–1.811) 0.018
Use of intravenous
inotrope at admission
1.353 (1.051–1.741) 0.019
Adjusted variables included age, sex, hypertension, diabetes mellitus, chronic kidney
disease, current smoker, body mass index, history of myocardial infarction,
cerebrovascular event, heart failure admission, ischemic cardiomyopathy, dilated
cardiomyopathy, valvular heart disease, atrial ﬁbrillation, left ventricular ejection fraction,
systolic blood pressure, New York Heart Association class ≥3, white blood cell count,
hemoglobin, use of b-blocker and/or RASB, and aldosterone antagonist. CI indicates
conﬁdence interval; HFmrEF, heart failure withmidrange ejection fraction; HR, hazard ratio;
NA, not applicable; RASB, renin-angiotensin system blocker; WBC, white blood cell.
*Harrell’s C-index of the Cox regression model for all-cause death was 0.723 (95% CI,
0.692–0.754).
Figure 3. Comparison of all-cause mortality at 3 years among
patients with heart failure with midrange ejection fraction accord-
ing to use of renin-angiotensin system blocker (RASB) and
b-blocker. The cumulative incidence of all-cause mortality was
compared among 4 groups divided according to use of RASB and/
or b-blocker. Red line denotes no drug group, green line denotes
b-blocker only group, black line denotes RASB only group, and blue
line denotes b-blocker and RASB groups.
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patients with acute HFmrEF. Both digoxin and nitrate were not
associated with reduced risk of mortality in patients with
HFmrEF (Figure S3).
Subgroup Analysis
Figure 4 presents the forest plot for various subgroups to
identify the consistency of outcomes of each GDMT. The
difference of rate of all-cause mortality between use of each
GDMT or not was consistent across the various subgroups
without signiﬁcant interaction.
Discussion
The current study evaluated the effect of GDMT, including
b-blocker, RASB, and AA at discharge, on clinical outcomes in
hospitalized patients with HFmrEF using patient-pooled cohorts
from 2 nationwide, prospective, multicenter registries in Korea.
Major ﬁndings of this study are as follows. First, prescription of
b-blocker or RASB at discharge was associated with reduced
risk of all-cause mortality in patients with HFmrEF. These
results were maintained after propensity score matching and
IPW analyses. Second, rates of all-cause mortality were not
signiﬁcantly different between prescription of AA at discharge
or not in patients with AHF with HFmrEF. Third, when dividing
patients into 4 groups according to use of b-blocker and/or
RASB, the b-blocker only, RASB only, and b-blocker plus RASB
groups had a signiﬁcantly lower all-cause mortality rate
compared with the no drug group. In addition, the lowest HR
and cumulative incidence of all-cause mortality were observed
in the b-blocker plus RASB group on multivariable analysis.
Characteristics and Prognosis of HFmrEF
HF is a clinical syndrome with various causes, characterized
by dyspnea, fatigue, and signs of volume overload. It is well
known that patients with HFpEF have different underlying
causes, demographics, comorbidities, and responses to
GDMT compared with those with HFrEF.24,25 However, the
prognosis and causes of HFmrEF, recently classiﬁed as a new
group, show conﬂicting results on the basis of previous
studies. Although most studies to evaluate the outcomes of
HFmrEF have shown that the HFmrEF group has an interme-
diate clinical proﬁle between HFrEF and HFpEF, several
studies have reported that the prognosis of HFmrEF is similar
to that of HFrEF,11–13 and other studies have shown that the
prognosis of HFmrEF is similar to that of HFpEF.14–16 In
addition, several studies have found that the prognosis of
HFmrEF may vary according to cause or clinical presentation.
Our group recently reported that prognosis of HFmrEF may
differ according to de novo HF or acute decompensated HF
using the KorAHF registry.17 Furthermore, Koh et al showed
that HFmrEF is overall an intermediate phenotype between
HFpEF and HFrEF, with the important exception of ischemic
Figure 4. Subgroup analysis among the total population, according to use of guideline-directed medical therapy. Comparative unadjusted
hazard ratios of all-cause mortality for subgroups in the overall population, according to use of b-blocker (red text), renin-angiotensin system
blocker (RASB; blue text), and aldosterone antagonist (AA; green text). Box denotes hazard ratio, and line denotes 95% conﬁdence interval. GFR
indicates glomerular ﬁltration rate; LVEF, left ventricular ejection fraction.
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cause, which was both more common and associated with
higher mortality in HFmrEF and HFrEF compared with
HFpEF.18 Consistent with previous studies, 47.6% of the
current study population had HFmrEF attributable to ischemic
cause, similar to that of HFrEF. This indirectly supports the
hypothesis that GDMT, such as b-blocker and RASB, which
are effective for reducing morbidity and mortality in acute
coronary syndrome, will also be effective for patients with
HFmrEF.
GDMT for HFmrEF
The current guidelines suggest that HFmrEF might be
managed in the same way as HFpEF because there is limited
evidence of the effect of GDMT in patients with HFmrEF.9
However, recent studies on the mortality beneﬁt of GDMT,
such as b-blocker or RASB in patients with HFmrEF, have
been reported. Patient-level meta-analysis of 11 double-blind,
randomized, placebo-controlled trials, stratiﬁed by baseline
LVEF and heart rhythm, demonstrated that b-blocker signif-
icantly improves the prognosis for patients with HFmrEF as
well as HFrEF.26 Furthermore, post hoc analysis of the
CHARM (Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity) trial also suggests that
candesartan improves outcomes in HFmrEF to a similar
degree as in HFrEF.27 In concordance with previous studies,
we identiﬁed the mortality beneﬁts of b-blocker and RASB in
hospitalized patients with HFmrEF using patient-pooled data
from 2 nationwide, prospective, multicenter registries. In
particular, our data showed the lowest HR of all-cause
mortality in the b-blocker plus RASB group after classifying
patients into 4 groups according to use of b-blocker and/or
RASB. This result would support the use of b-blocker and
RASB in HFmrEF to reduce the risk of mortality, similar to
HFrEF. Future large randomized controlled trials for the
effects of b-blocker and RASB in patients with HFmrEF will be
useful to conﬁrm our results. In addition, future guidelines for
patients with HFmrEF could be changed to treatment
strategies similar to those for HFrEF, not HFpEF, on the basis
of the results of several trials, including the present study.
AAs, including spironolactone and eplerenone, are associated
with reducingmorbidity andmortality in patientswith systolic HF
(EF <35%) in addition to recommended therapy.7,8 However, the
TOPCAT (Treatment of Preserved Cardiac Function Heart Failure
With anAldosteroneAntagonist) trial failed toprove the beneﬁt of
spironolactone therapy in patients with HFpEF (EF ≥45%).28
Although post hoc analysis from the TOPCAT trial, stratiﬁed by
EF, showed that the potential efﬁcacy of spironolactone tended
to be maximized at the lower end of the LVEF spectrum29; to
date, there are no data comparing the outcomes of use of AAs in
patients with HFmrEF. The present study demonstrated that the
risk ofmortality did not differ betweenuse ofAAor not in patients
with HFmrEF. However, observational studies consistently show
a lack of beneﬁt with AA, but randomized controlled trials
consistently showa beneﬁt for patientswithHFrEF. Perhaps, this
result might be a failure of method rather than a lack of beneﬁt
from AA. Because AAs were recommended to be prescribed to
thosewho remained symptomatic taking themedication of RASB
and b-blocker, those with AAs might be more severe patients
with worse prognosis, although we performed propensity
matching analysis. In addition, the failure to reach the statistical
signiﬁcance of the effect of AA use on clinical outcome might be
because of type II error. In this regard, well-designed randomized
controlled trials focusing on the effect of AA in patients with
HFmrEF will be needed.
Limitations
The current study had several limitations. First, the nonran-
domized nature of registry data could introduce selection bias,
and use of GDMTwas based on physician’s discretion. Although
we performed various risk adjustments for potential confound-
ing factors, including propensity score matching and IPW
analysis, we cannot correct for unmeasured variables in the
present study. Second, LVEF was measured by various
methods, including biplane Simpson technique, M-mode, and
visual estimation, rather than by a single method. However, this
variability may only minimally affect the present study, because
LVEF was only used to stratify the groups. Third, there are no
data on doses or on postdischarge initiation or discontinuation
of GDMT. Fourth, the analysis was performed on the pooled
data set from 2 distinct registries that captured hospitalizations
from 2004 to 2009 and from 2011 to 2014. Furthermore,
baseline characteristics and clinical outcomes slightly differ
between the 2 registries (Table S2). However, there was no
change of medical treatment strategy for patients with HF
between 2004 and 2009 and between 2011 and 2014. Finally,
because the current study only included patients who were
admitted for AHF, we were not able to extrapolate the effects of
GDMT on patients with chronic stable HF.
Conclusions
For the treatment of acute HFmrEF after hospitalization,
b-blocker and RASB at discharge were associated with
reduced risk of all-cause mortality. However, treatment with
AA at discharge was not associated with reduced risk of all-
cause mortality for the management of HFmrEF.
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Table S1. Standardized differences of variables used in PS matching and IPW adjustment to adjust for baseline 
differences. 
 Beta-blocker at discharge 
Standardized mean differences, % 
Renin angiotensin system blocker at discharge 
Standardized mean differences, % 
Aldosterone antagonist at discharge 
Standardized mean differences, % 
 Unadjusted PS matched IPW-
adjusted 
Unadjusted PS matched IPW-
adjusted 
Unadjusted PS matched IPW-
adjusted 
Age (yr) 8.7 6.0 0.1 -6.6 -1.8 -3.9 1.2 -1.2 -1.6 
Male 0.5 -3.7 -2.2 -0.9 -0.7 -2.2 -20.8 1.1 -2.9 
Body mass index (kg/m2) -13.8 -2.2 2.8 -20.2 -4.3 -2.3 -4.0 -0.9 4.4 
Current smoker -10.6 -4.0 -0.2 9.9 -4.4 -1.9 -7.8 -0.8 1.8 
Hypertension -16.6 -4.3 0.7 -23.1 -4.0 -2.7 -11.0 -1.7 -5.1 
Diabetes mellitus -13.3 3.4 0.4 -7.9 -3.5 -1.9 -14.0 -4.7 0.8 
Chronic kidney disease -6.1 0.8 1.3 12.1 0.9 -3.0 -48.3 -3.1 -1.1 
Previous myocardial infarction -13.2 0.8 2.1 -10.2 -4.7 -3.5 -15.6 -2.4 -3.3 
Previous cerebrovascular accident -12.4 0 -0.8 -10.5 -8.0 0.2 -4.4 -0.8 -1.3 
Previous heart failure admission 11.3 1.2 -0.2 -13.3 -1.6 0.2 14.4 3.1 -0.7 
De novo acute heart failure 10.3 2.7 1.0 4.1 -3.3 -1.4 13.1 3.9 -0.6 
NYHA -13.0 6.3 0.9 -9.9 1.6 -1.7 19.6 1.1 1.8 
Ischemic cardiomyopathy -34.8 -7.2 0.5 -8.3 -2.0 -4.3 -32.7 -7.4 0.2 
Dilated cardiomyopathy 3.8 -2.6 -2.1 -2.6 -1.7 3.3 15.9 9.0 0.4 
Valvular heart disease 23.5 4.0 0.3 14.2 4.3 2.9 6.6 -5.3 1.2 
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Atrial fibrillation 19.0 0.6 -0.3 5.8 0.7 0.3 12.9 -0.6 2.1 
Systolic blood pressure (mmHg) -4.9 -0.6 -0.4 -33.5 1.6 -2.6 -9.3 -2.5 -2.6 
Left ventricular ejection fraction (%) -1.1 0.6 -2.0 -5.5 -5.7 -5.4 4.4 -1.3 4.3 
WBC (/mm3) -20.9 1.1 0.8 10.4 2.7 -0.4 -21.9 -1.2 -2.8 
Creatinine (mg/dL) -7.2 0.6 0.8 6.2 0.9 -4.8 -76.9 -8.2 1.8 
Hemoglobin (g/dL) -1.9 -6.2 -1.3 0.2 2.4 3.0 9.2 4.2 -5.7 
IV diuretic 0.8 0 2.1 -4.9 5.8 0.9 30.1 -6.9 2.2 
IV inotrope 15.5 5.4 0.8 46.3 6.1 -0.6 -14.8 -4.8 0.3 
Mechanical ventilation 4.1 1.6 -0.7 17.5 3.6 -1.5 -5.5 0.9 -0.4 
Transfusion 7.2 5.3 1.6 22.7 0.8 -2.2 -10.2 -1.5 1.1 
ICU admission -10.1 3.2 1.9 16.0 2.0 -2.5 -17.0 -8.9 2.2 
Beta-blocker NA NA NA -47.1 -4.7 1.0 8.1 1.7 1.0 
Renin angiotensin system blocker -42.5 -6.4 -0.2 NA NA NA 13.1 4.2 0.3 
Aldosterone antagonist -10.1 -4.4 -0.7 -13.4 -4.9 2.7 NA NA NA 
ICU = intensive care unit; IPW = inverse probability weighted; IV = intra-venous; NYHA = New York Heart Association; PS = propensity score; WBC = white blood cell 
  
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
Table S2. Comparison of KorHF and KorAHF populations. 
Variables KorHF (N=301) KorAHF (N=843) P value 
Demographics   
Age (yr) 69.8 ± 14.5 71.0 ± 12.9 0.233 
Male 135 (44.9%) 397 (47.1%) 0.547 
Body mass index (kg/m2) 22.9±3.6 23.4±3.7 0.051 
Cardiovascular risk factors   
Current smoker 56 (18.6%) 111 (13.2%) 0.028 
Hypertension 154 (51.2%) 538 (63.8%) <0.001 
Diabetes mellitus 100 (33.2%) 302 (35.8%) 0.458 
Chronic kidney disease 34 (11.3%) 133 (15.8%) 0.073 
Previous myocardial infarction 45 (15.0%) 145 (17.2%) 0.418 
Previous cerebrovascular accident 30 (10.0%) 133 (15.8%) 0.017 
Previous heart failure admission 6 (2.0%) 242 (28.7%) <0.001 
Presentation and etiology of heart failure   
De novo acute heart failure 87 (28.9%) 370 (43.9%) <0.001 
NYHA ≥3 196 (65.1%) 705 (83.6%) <0.001 
  Ischemic cardiomyopathy 170 (56.5%) 374 (44.4%) <0.001 
  Dilated cardiomyopathy 21 (7.0%) 33 (3.9%) 0.046 
  Valvular heart disease 40 (13.3%) 122 (14.5%) 0.682 
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  Arrhythmia 39 (13.0%) 294 (34.9%) <0.001 
  Atrial fibrillation 32 (10.6%) 263 (31.2%) <0.001 
Hemodynamic parameters at admission   
Systolic blood pressure (mmHg) 134.8±32.1 137.7±31.9 0.180 
Diastolic blood pressure (mmHg) 80.1±18.0 79.8±19.5 0.784 
Pulse rate (beats/min) 91.2±28.0 92.3±26.6 0.527 
Left ventricular ejection fraction (%) 44.1±2.9 44.2±2.8 0.359 
Laboratory data   
  WBC (/mm3) 9006.3±4557.1 8874.9±4187.0 0.654 
  Creatinine (mg/dL) 1.6±1.5 1.6±1.7 0.805 
  Hemoglobin (g/dL) 11.9±2.2 12.0±2.4 0.642 
  NT-proBNP (pg/mL) 9277.4±10566.6 9084.5±10293.1 0.822 
In-hospital management   
  IV diuretic 209 (69.4%) 618 (73.3%) 0.225 
  IV inotrope 70 (23.3%) 195 (23.1%) >0.999 
  Mechanical ventilation 24 (8.0%) 101 (12.0%) 0.071 
  Transfusion 11 (3.7%) 187 (22.2%) <0.001 
  ICU admission 112 (37.2%) 431 (51.1%) <0.001 
  Length of stay (days) 9.0 (6.0–15.5) 9.0 (6.0–14.0) 0.523 
Medications at discharge   
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  Beta-blocker 135 (44.9%) 485 (57.5%) <0.001 
  Renin angiotensin system blocker 163 (54.2%) 574 (68.1%) <0.001 
  Aldosterone antagonist 87 (28.9%) 346 (41.0%) <0.001 
  Loop diuretic 158 (52.5%) 740 (87.8%) <0.001 
Outcomes    
  All-cause mortality 81 (26.9%) 273 (32.4%) 0.091 
Values are mean ± SD, median (Q1-Q3), or n (%). 
ICU = intensive care unit; IPW = inverse probability weighted; IV = intra-venous; NYHA = New York Heart Association; PS = propensity score; WBC = white blood cell 
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Figure S1. Comparison of All-cause Mortality at 3 Years According to Use of Guideline Directed Medical Therapy Among 
Patients with Heart Failure with Preserved Ejection Fraction. 
 
Kaplan-Meier curves for all-cause mortality of AHF patients with HFpEF according to use of BB (blue line) or no BB (red line) (A), use of 
RASB (blue line) or no RASB (red line) (B), and use of AA (blue line) or no AA (red line) (C) are presented. 
AA= aldosterone antagonist; BB= beta-blocker; HFpEF= heart failure with preserved ejection fraction; RASB= renin angiotensin system 
blocker  
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
Figure S2. Comparison of All-cause Mortality at 3 Years According to Use of Guideline Directed Medical Therapy Among 
Patients with Heart Failure with Reduced Ejection Fraction. 
 
Kaplan-Meier curves for all-cause mortality of AHF patients with HFrEF according to use of BB (blue line) or no BB (red line) (A), use of 
RASB (blue line) or no RASB (red line) (B), and use of AA (blue line) or no AA (red line) (C) are presented. 
AA= aldosterone antagonist; AHF = acute heart failure; BB= beta-blocker; HFrEF= heart failure with reduced ejection fraction; RASB= renin 
angiotensin system blocker  
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Figure S3. Comparison of All-cause Mortality at 3 Years According to Use of Digoxin and Nitrate Among Patients with 
Heart Failure with Mid-Range Ejection Fraction. 
 
Kaplan-Meier curves for all-cause mortality of AHF patients with HFmrEF according to use of digoxin (blue line) or no digoxin (red line) (A), 
and use of nitrates (blue line) or no nitrates (red line) (B) are presented. 
AA= aldosterone antagonist; AHF = acute heart failure; BB= beta-blocker; HFpEF= heart failure with preserved ejection fraction; RASB= 
renin angiotensin system blocker 
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